Human Deleted in lung and esophageal cancer protein 1 (DLEC1) ELISA Kit
| Product Name | Human Deleted in lung and esophageal cancer protein 1 (DLEC1) ELISA Kit |
|---|---|
| Description | DLC1 contains 37 exons and spans approximately 59 kb. The predicted DLC1 protein contains 1,755 amino acids. Expression of DLC1 significantly suppressed the growth of 4 different cancer cell lines. Northern blot analysis revealed that DLC1 was expressed as 6- and 8-kb mRNAs in all tissues tested, most abundantly in prostate and testis. the 8-kb mRNA and several other alternatively spliced DLC1 transcripts contain disrupted coding regions and are likely to encode nonfunctional proteins. RT-PCR experiments indicated that 33% of primary lung, esophageal, and renal cancers and cancer cell lines tested either lacked DLC1 transcripts entirely or contained increased levels of nonfunctional DLC1 mRNA. The authors concluded that aberrant transcription of DLC1 may be involved in carcinogenesis of the lung, esophagus, and kidney. This assay has high sensitivity and excellent specificity for detection of Human DLEC1. No significant cross-reactivity or interference between Human DLEC1 and analogues was observed. |
| Synonyms | DLC1, F56, deleted in lung cancer 1 |
| Method | Sandwich ELISA |
| Detection Range | Request Information |
| Sensitivity | Request Information |
| Reactivity | Human |
| Sample Types | Serum, Plasma, Other biological fluids. |
| Background | DLC1 contains 37 exons and spans approximately 59 kb. The predicted DLC1 protein contains 1,755 amino acids. Expression of DLC1 significantly suppressed the growth of 4 different cancer cell lines. Northern blot analysis revealed that DLC1 was expressed as 6- and 8-kb mRNAs in all tissues tested, most abundantly in prostate and testis. the 8-kb mRNA and several other alternatively spliced DLC1 transcripts contain disrupted coding regions and are likely to encode nonfunctional proteins. RT-PCR experiments indicated that 33% of primary lung, esophageal, and renal cancers and cancer cell lines tested either lacked DLC1 transcripts entirely or contained increased levels of nonfunctional DLC1 mRNA. The authors concluded that aberrant transcription of DLC1 may be involved in carcinogenesis of the lung, esophagus, and kidney. |
| Supplier | Abebio |
All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.
